药品注册申请号:021129
申请类型:NDA (新药申请)
申请人:VIATRIS
申请人全名:VIATRIS SPECIALTY LLC
产品信息
产品号商品名活性成分剂型/给药途径规格/剂量参比药物(RLD)生物等效参考标准(RS)治疗等效代码该申请号批准日期该产品号批准日期市场状态
001 NEURONTIN GABAPENTIN SOLUTION;ORAL 250MG/5ML Yes Yes AA 2000/03/02 2000/03/02 Prescription
批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
提交状态日期提交号审批结论申请内容分类审评优先级;罕用药状态通知信、审评文件、说明书、包装标签备注
2024/07/12 SUPPL-56(补充) Approval Labeling STANDARD
2020/12/16 SUPPL-50(补充) Approval Labeling STANDARD
2020/04/02 SUPPL-49(补充) Approval Labeling 901 REQUIRED
2017/10/18 SUPPL-46(补充) Approval Labeling STANDARD
2017/03/24 SUPPL-44(补充) Approval Labeling STANDARD
2015/09/14 SUPPL-42(补充) Approval Labeling STANDARD
2015/04/21 SUPPL-43(补充) Approval Labeling STANDARD
2014/08/18 SUPPL-39(补充) Approval Labeling STANDARD
2014/04/15 SUPPL-41(补充) Approval Manufacturing (CMC) STANDARD
2013/07/18 SUPPL-38(补充) Approval Manufacturing (CMC) STANDARD
2013/05/01 SUPPL-37(补充) Approval Labeling STANDARD
2013/05/01 SUPPL-36(补充) Approval Labeling UNKNOWN
2013/05/01 SUPPL-35(补充) Approval Labeling STANDARD
2011/08/10 SUPPL-33(补充) Approval Labeling UNKNOWN
2011/03/01 SUPPL-22(补充) Approval Labeling STANDARD
2010/10/11 SUPPL-29(补充) Approval Labeling STANDARD
2009/04/23 SUPPL-27(补充) Approval Labeling 901 REQUIRED
2006/05/03 SUPPL-20(补充) Approval Labeling STANDARD
2005/02/18 SUPPL-16(补充) Approval Labeling STANDARD
2002/12/19 SUPPL-13(补充) Approval Manufacturing (CMC) STANDARD
2002/10/24 SUPPL-11(补充) Approval Manufacturing (CMC) STANDARD
2002/08/15 SUPPL-10(补充) Approval Efficacy STANDARD
2002/01/30 SUPPL-9(补充) Approval Labeling STANDARD
2002/01/18 SUPPL-8(补充) Approval Manufacturing (CMC) STANDARD
2001/04/26 SUPPL-6(补充) Approval Manufacturing (CMC) STANDARD
2000/10/12 SUPPL-5(补充) Approval Efficacy STANDARD
2000/09/19 SUPPL-4(补充) Approval Manufacturing (CMC) STANDARD
2000/03/02 ORIG-1(原始申请) Approval Type 3 - New Dosage Form STANDARD
与本品相关的专利信息(来自FDA橙皮书Orange Book)
关联产品号专利号专利过期日是否物质专利是否产品专利专利用途代码撤销请求提交日期专利下载备注
001 4894476 2008/05/02 PDF格式**本条是由Drugfuture回溯的历史信息**
4894476*PED 2008/11/02 PDF格式**本条是由Drugfuture回溯的历史信息**
6054482 2017/04/25 PDF格式**本条是由Drugfuture回溯的历史信息**
6054482*PED 2017/10/25 PDF格式**本条是由Drugfuture回溯的历史信息**
7256216 2022/05/28 Y PDF格式**本条是由Drugfuture回溯的历史信息**
7256216*PED 2022/11/28 PDF格式**本条是由Drugfuture回溯的历史信息**
与本品相关的市场独占权保护信息
关联产品号独占权代码失效日期备注
与本品治疗等效的药品
活性成分:GABAPENTIN 剂型/给药途径:SOLUTION;ORAL 规格:250MG/5ML 治疗等效代码:AA
申请号产品号申请类型商品名活性成分剂型/给药途径规格市场状态RLDRSTE Code产品号批准日期申请人
021129 001 NDA NEURONTIN GABAPENTIN SOLUTION;ORAL 250MG/5ML Prescription Yes Yes AA 2000/03/02 VIATRIS
078974 001 ANDA GABAPENTIN GABAPENTIN SOLUTION;ORAL 250MG/5ML Prescription No No AA 2011/02/18 MISSION PHARMACAL
202024 001 ANDA GABAPENTIN GABAPENTIN SOLUTION;ORAL 250MG/5ML Prescription No No AA 2012/03/23 AMNEAL PHARMS
076403 001 ANDA GABAPENTIN GABAPENTIN SOLUTION;ORAL 250MG/5ML Prescription No No AA 2012/05/01 ACELLA PHARMS LLC
076672 001 ANDA GABAPENTIN GABAPENTIN SOLUTION;ORAL 250MG/5ML Prescription No No AA 2013/07/03 TARO
091286 001 ANDA GABAPENTIN GABAPENTIN SOLUTION;ORAL 250MG/5ML Prescription No No AA 2016/03/14 BELCHER
216492 001 ANDA GABAPENTIN GABAPENTIN SOLUTION;ORAL 250MG/5ML Prescription No No AA 2023/01/18 RUBICON
217682 001 ANDA GABAPENTIN GABAPENTIN SOLUTION;ORAL 250MG/5ML Prescription No No AA 2024/01/17 ANNORA PHARMA
更多信息
药品NDC数据与药品包装、标签说明书
©2006-2024 DrugFuture->U.S. FDA Drugs Database